Novartis Ag (NVS) Net Cash Flow (2009 - 2026)
Novartis Ag (NVS) posted Net Cash Flow of $757.0 million for Q2 2026, up 135.98% sequentially from -$2.1 billion in Q4 2025, and up 195.58% YoY from $256.1 million in Q2 2025.
Novartis Ag (NVS) Net Cash Flow (2009 - 2026) Analysis & Trends
Novartis Ag has reported Net Cash Flow for 18 years, with the latest figure at $757.0 million in Q2 2026.
- Quarterly Net Cash Flow rose 195.58% year-over-year to $757.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.2 billion (up 66.3% YoY) and the FY2025 annual result came in at -$600.0 million, up 63.33% from the prior year.
- Net Cash Flow grew to $757.0 million in Q2 2026 per NVS's latest filing, from -$2.1 billion in the prior quarter.
- Over five years, Net Cash Flow peaked at $757.0 million in Q2 2026 and troughed at -$10.2 billion in Q2 2022.
- A 5-year average of -$1.8 billion and a median of -$860.0 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow plunged 974.6% in 2024, then soared 195.58% in 2026.
- Over 5 years, Net Cash Flow stood at -$10.2 billion in 2022, then surged by 95.13% to -$496.0 million in 2023, then slumped by 974.6% to -$5.3 billion in 2024, then soared by 60.53% to -$2.1 billion in 2025, then soared by 135.98% to $757.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $757.0 million, -$2.1 billion, and -$860.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 757.00 Mn |
| Jun 30, 2026 | 757.00 Mn |
| Dec 31, 2025 | -2.10 Bn |
| Dec 31, 2025 | -2.10 Bn |
| Sep 30, 2025 | -860.00 Mn |
| Sep 30, 2025 | -860.00 Mn |
| Jun 30, 2025 | -792.00 Mn |
| Jun 30, 2025 | -792.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Dec 31, 2024 | -5.33 Bn |
| Dec 31, 2024 | -5.33 Bn |
| Sep 30, 2024 | -756.00 Mn |
| Sep 30, 2024 | -756.00 Mn |
| Jun 30, 2024 | -1.53 Bn |
| Jun 30, 2024 | -1.53 Bn |
| Mar 31, 2024 | -899.00 Mn |
| Mar 31, 2024 | -899.00 Mn |
| Dec 31, 2023 | -496.00 Mn |
| Dec 31, 2023 | -496.00 Mn |